Japan's JCR starts Phase I Fabry's Disease biosimilar study

SINGAPORE--JCR Pharmaceuticals has launched a Phase I clinical trial in Japan for JR-051, a recombinant alpha-galactosidase A, as an enzyme replacement therapy for Fabry's disease, the company said on Feb. 10.

The drug is a biosimilar version of Genzyme Japan's Fabrazyme (agalsidase beta) with a timeline of 2017 for regulatory approval.

The rare disease caused by the deficiency of the alpha-galactosidase A enzyme, is characterized by pain in the extremities, clouding of the cornea, renal failure and cardiac dysfunction. Roughly 300 patients in Japan and 5,000-10,000 worldwide suffer from the disease, according to JCR.

Related Stories:
GlaxoSmithKline bails out of its Fabry deal with Amicus
Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium
TPG Biotech to Fund Development of JCR Pharmaceuticals Drug Candidates